Edematogenic, hemorrhagic, and myonecrotic effects of the Pseudocerastes persicus venom in mice Edematogenic effects of P.persicus venom
Iranian Journal of Pharmaceutical Sciences,
Vol. 22 No. 1 (2026),
26 January 2026
,
Page 291-298
https://doi.org/10.22037/ijps.v22i1.50145
Abstract
Snakebites represent a significant public health concern in Iran, where the Persian horned viper (Pseudocerastes persicus) is endemic. This study aimed to evaluate, for the first time, the local pathological effects of its venom in mice. Paw edema was induced in different groups (n = 6 in each group) by intraplantar injection of venom (10, 50, and 100 µg/paw). Increase in paw thickness (%) was measured using a digital caliper over time. Pathological changes (blood cell extravasation, edema, and leukocyte infiltration at the injection site) were assessed via hematoxylin and eosin staining. Pentavalent snake antivenoms (RVSRI and PSA) were tested by preincubation with venom or intraperitoneal administration pre- or post-exposure. Subcutaneous injections of the Pseudocerastes persicus crude venom 10-100 µg/paw resulted in marked dose-dependent paw edema in mice. As a whole, both antivenoms diluted in normal saline (100 µl) significantly reduced paw edema, and hemorrhagic and histological properties were reduced when incubated with the challenge dose (50 µg) for 30 minutes. However, when infused intraperitoneally, 10 minutes before or immediately after venom exposure, both failed to neutralize the pathological changes. In parallel settings, intramuscular and subcutaneous injections of the venom (50 µg) into the gastrocnemius muscle and the dorsal areas of anesthetized mice caused severe changes. According to our preliminary study, this venom exhibits extreme edematogenic, hemorrhagic, and myonecrotic effects, necessitating further investigation to develop effective treatment strategies for envenomation. Understanding these dynamics is crucial for introducing effective antivenoms and, if necessary, new therapeutic modalities, given economic constraints and the need for therapeutic interventions in the management of snakebites.
- Persian horned viper
- Paw edema
- Venom
- Antivenom
How to Cite
References
1. Dehghani R, Fathi B, Shahi MP, Jazayeri M. Ten years of snakebites in Iran. Toxicon. 2014;90:291-8.
2. Moradi N, Rastegar-Pouyani N, Rastegar-Pouyani E. Geographic variation in the morphology of Macrovipera lebetina (Linnaeus, 1758)(Ophidia: Viperidae) in Iran. Acta Herpetologica. 2014;9(2):187-202.
3. Kazemi SM, Hosseinzadeh MS, Weinstein SA. Identifying the geographic distribution pattern of venomous snakes and regions of high snakebite risk in Iran. Toxicon. 2023;231:107197.
4. De Pous P, Simó-Riudalbas M, Els J, Jayasinghe S, Amat F, Carranza S. Phylogeny and biogeography of Arabian populations of the Persian horned viper Pseudocerastes persicus (Duméril, Bibron & Duméril, 1854). Zoology in the Middle East. 2016;62(3):231-8.
5. Kazemi SM, Jahan-Mahin MH, Zangi B, Khozani RS, Warrell DA. A case of envenoming by a Persian false-horned viper Pseudocerastes persicus (Duméril, Bibron & Duméril, 1854) (Serpentes: Viperidae) in Southeastern Iran. Toxicon. 2023;223:107009.
6. Samianifard M, Tahoori F, Emami T, Nazari A. Proteomic Analysis and Immunoprofiling of Persian Horned Viper Venom, Pseudocerastes Persicus, from Central Part of Iran. Archives of Razi Institute. 2024;79(1):154.
7. Golchinfar F, Madani R, Nazari Shirvan A, Ghanizadeh A, Emami T. Study of Protease Properties in Pseudocereastes Percicus Venom. Veterinary Research & Biological Products. 2020;33(1):118-27.
8. Banijamali SE, Amininasab M, Elmi MM. Characterization of a new member of kunitz-type protein family from the venom of Persian false-horned viper, Pseudocerastes persicus. Archives of Biochemistry and Biophysics. 2019;662:1-6.
9. Theakston R, Kamiguti A. Viper envenoming: evaluation of treatment by restoration of haemostasis and venom clearance. Journal of venomous animals and Toxins. 1998;4(2):94-111.
10. Abouyannis M, Aggarwal D, Lalloo DG, Casewell NR, Hamaluba M, Esmail H. Clinical outcomes and outcome measurement tools reported in randomised controlled trials of treatment for snakebite envenoming: A systematic review. PLOS Neglected Tropical Diseases. 2021;15(8):e0009589.
11. Perret-Gentil M. Mouse Biomethodology. Laboratory Animal Resources Center. 2013;24.
12. Zhang X, Retyunskiy V, Qiao S, Zhao Y, Tzeng C-M. Alloferon-1 ameliorates acute inflammatory responses in λ-carrageenan-induced paw edema in mice. Scientific reports. 2022;12(1):16689.
13. Shaban S, Taheri F, Mehrpour O, Chahkandi T. A Seven-year Epidemiological Study of Snakebite Cases Among Children and Adolescents in South Khorasan, Eastern Iran. International Journal of Medical Toxicology and Forensic Medicine. 2025;15(1):E45734.
14. Dehghani R, Rabani D, Shahi MP, Jazayeri M, Bidgoli MS. Incidence of snake bites in Kashan, Iran during an eight year period (2004-2011). Archives of trauma research. 2012;1(2):67.
15. De Aquino Nery MD, de Aquino HD, Ribeiro RdTM, de Aquino Nery E, de Menezes DB, Ximenes RM, et al. Edematogenic and myotoxic activities induced by snake venom of Philodryas nattereri from the Northeast of Brazil. Fundamental Toxicological Sciences. 2014;1(1):7-13.
16. Lomonte B, Tarkowski A, Hanson LÅ. Host response to Bothrops asper snake venom: analysis of edema formation, inflammatory cells, and cytokine release in a mouse model. Inflammation. 1993;17(2):93-105.
17. Abd El-Aziz TM, Shoulkamy MI, Hegazy AM, Stockand JD, Mahmoud A, Mashaly AM. Comparative study of the in vivo toxicity and pathophysiology of envenomation by three medically important Egyptian snake venoms. Archives of toxicology. 2020;94:335-44.
18. Tonello F, Rigoni M. Cellular mechanisms of action of snake phospholipase A2 toxins. Snake venoms. 2017:49-65.
19. Costa SK, Camargo EA, Antunes E. Inflammatory action of secretory phospholipases A2 from snake venoms. Toxins and Drug Discovery. 2017:35-52.
20. Sandesha VD, Darshan B, Tejas C, Girish KS, Kempaiah K. A comparative cross-reactivity and paraspecific neutralization study on Hypnale hypnale, Echis carinatus, and Daboia russelii monovalent and therapeutic polyvalent anti-venoms. PLOS neglected tropical diseases. 2022;16(3):e0010292.
21. Khourcha S, Hilal I, Elbejjaj I, Karkouri M, Safi A, Hmyene A, et al. Insight into the Toxicological and Pathophysiological Effects of Moroccan Vipers' Venom: Assessing the Efficacy of Commercial Antivenom for Neutralization. Tropical Medicine and Infectious Disease. 2023;8(6):302.
22. Gutiérrez J, Rojas G, Lomonte B, Gené J, Cerdas L. Comparative study of the edema-forming activity of Costa Rican snake venoms and its neutralization by a polyvalent antivenom. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology. 1986;85(1):171-5.
23. Rucavado A, Lomonte B. Neutralization of myonecrosis, hemorrhage, and edema induced by Bothrops asper snake venom by homologous and heterologous pre-existing antibodies in mice. Toxicon. 1996;34(5):567-77.
24. Appiah B. Snakebite neglect rampant in Africa. CMAJ; 2012.
- Abstract Viewed: 43 times
- IJPS_Volume22_Issue1_Pages291-298 Downloaded: 16 times